1. Home
  2. GSRFU vs ICUCW Comparison

GSRFU vs ICUCW Comparison

Compare GSRFU & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSRFU
  • ICUCW
  • Stock Information
  • Founded
  • GSRFU N/A
  • ICUCW N/A
  • Country
  • GSRFU United States
  • ICUCW United States
  • Employees
  • GSRFU N/A
  • ICUCW 18
  • Industry
  • GSRFU
  • ICUCW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSRFU
  • ICUCW Health Care
  • Exchange
  • GSRFU Nasdaq
  • ICUCW Nasdaq
  • Market Cap
  • GSRFU N/A
  • ICUCW N/A
  • IPO Year
  • GSRFU 2025
  • ICUCW 2021
  • Fundamental
  • Price
  • GSRFU $10.29
  • ICUCW $0.03
  • Analyst Decision
  • GSRFU
  • ICUCW
  • Analyst Count
  • GSRFU 0
  • ICUCW 0
  • Target Price
  • GSRFU N/A
  • ICUCW N/A
  • AVG Volume (30 Days)
  • GSRFU N/A
  • ICUCW N/A
  • Earning Date
  • GSRFU N/A
  • ICUCW N/A
  • Dividend Yield
  • GSRFU N/A
  • ICUCW N/A
  • EPS Growth
  • GSRFU N/A
  • ICUCW N/A
  • EPS
  • GSRFU N/A
  • ICUCW N/A
  • Revenue
  • GSRFU N/A
  • ICUCW N/A
  • Revenue This Year
  • GSRFU N/A
  • ICUCW N/A
  • Revenue Next Year
  • GSRFU N/A
  • ICUCW N/A
  • P/E Ratio
  • GSRFU N/A
  • ICUCW N/A
  • Revenue Growth
  • GSRFU N/A
  • ICUCW N/A
  • 52 Week Low
  • GSRFU N/A
  • ICUCW N/A
  • 52 Week High
  • GSRFU N/A
  • ICUCW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GSRFU N/A
  • ICUCW 42.56
  • Support Level
  • GSRFU N/A
  • ICUCW $0.03
  • Resistance Level
  • GSRFU N/A
  • ICUCW $0.03
  • Average True Range (ATR)
  • GSRFU 0.00
  • ICUCW 0.01
  • MACD
  • GSRFU 0.00
  • ICUCW -0.00
  • Stochastic Oscillator
  • GSRFU 0.00
  • ICUCW 30.10

About ICUCW SeaStar Medical Holding Corporation Warrant

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: